KBC Securities - ArGEN-X SE (ARGX) argenx Vyvgart 2Q25 sales show solid CSS beat

Report

KBC Securities

Jacob Mekhael

argenx Vyvgart 2Q25 sales show solid CSS beat

argenx reported another strong quarter with Vyvgart sales coming in at $ 949m, beating CSS by approx. 10%. argenx reached operating profitability for the 4th consecutive quarter, and is on track for FY25 profitability. Pipeline timelines are reiterated and we look ahead to the upcoming readouts in seronegative gMG (2H25), as well as PoC results in lupus nephritis (Vyvgart, 4Q25) and delayed graft function (empa, 2H25). ARGX-119 R&D day set for 16 September. Accumulate/ € 670 TP reiterated.

31/07/2025 1 EN

Underlying

ArGEN-X SE

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

See profile

NL0010832176 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : ARGX BB, NXFIL NA, JDEP NA

: ARGX BB, NXFIL NA, JDEP NA

August 25, 2025 August 25, 2025 1 EN

KBC Securities

argenx Vyvgart meets primary endpoint in snMG paving path for label expansion

argenx announced positive topline data from the pivotal ADAPT SERON study of Vyvgart in AchR-Ab seronegative gMG (snMG), showing a statistically significant improvement vs. placebo (p-value=0.0068) on the primary endpoint of MG-ADL. The positive topline results do not come as a surprise, and confirm previously reported pooled analysis showing improvements in the MG-ADL score in this gMG sub-population. The company plans to file for label expansion with the FDA, and estimates the commercial opportunity for seronegative gMG could add 11K patients on top of the 17K addressable population at launc...

August 25, 2025 August 25, 2025 1 EN

GlobeNewsWire

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to be submitted to U.S. Food and Drug Administration (FDA) by end of 2025 August 25, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving t...

August 25, 2025 August 25, 2025 1 EN

Morning Notes : EXM BB, WDP BB, DEME BB

: EXM BB, WDP BB, DEME BB

14h / 33m 14h / 33m 1 EN

Guy Sips

Guy Sips

DEME Good set of 1H25 results but impacted by some non-recurring elements

We maintain our positive stance (Buy € 175 TP) as after a good set of 1H25 results, DEME indicated that its operations remain robust and they still expect full-year turnover to be at least in line with FY24 and now anticipate FY25 EBITDA margin to slightly exceed 20% (was before at least in line with FY24). FY25 CapEx remains forecasted at +/- €300m, excluding the expenditures for the Havfram acquisition and the completion and delivery of its two vessels, which will significantly boost DEME's sustainable operational capacity. DEME indicated that the integration is progressing well and the cons...

14h / 48m 14h / 48m 1 EN

Wim Lewi

Wim Lewi

AEX from 25 to 30, place your bets Our candidates for the AEX expansion

The AEX is set to expand from 25 to 30 constituents starting on 23rd September, announcement on 9th September after close. This marks a significant change since its last expansion in 1994. The new rule book was published on 22/08/25 and leaves some room for interpretation for companies that have another primary listing (WDP). We believe that WDP meets the requirement for “reference market”. The expansion will be based on Free Float Market Capitalization, with a buffer zone to manage transitions. Five companies from the AMX index (which tracks mid-cap stocks) are expected to promote to the AEX....

14h / 51m 14h / 51m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

argenx Vyvgart 2Q25 sales show solid CSS beat

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ARGX BB, NXFIL NA, JDEP NA

argenx Vyvgart meets primary endpoint in snMG paving path for label expansion

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Morning Notes : EXM BB, WDP BB, DEME BB

DEME Good set of 1H25 results but impacted by some non-recurring elements

AEX from 25 to 30, place your bets Our candidates for the AEX expansion

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe